|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Genzyme Corporation, a leading biotechnology company. |
|---|---|
| Transferring Party | The adeno-associated virus technology of Avigen Inc. (NASDAQ: AVGN), a biotech developer of small molecule therapeutics for treating neurological conditions. |
| Sector | Biopharmaceuticals |
| Date | December 31, 2005 |
| Analysis In this $12 million cash deal (plus royalties and milestone payments), Genzyme acquires a broad gene therapy patent estate, a Phase I/II program in Parkinson's disease and a clinical collaboration in hemophilia. Recently, Genzyme also bought Genesys Inc.'s manufacturing operation for $3.2 million to support the growth of its gene-therapy programs. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |